β-blockers in congestive heart failure

Bibliography

• American Heart Association: 1997 Heart and Stroke: Statis-tical Update. AHA, Dallas (1996):1–29.
   Google Scholar
• KANNEL WB, BELANGER AJ: Epidemiology of heart failure. Am. Heart J. (1991) 121:951–957.
   PubMed Web of Science ®Google Scholar
• PACKER M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. (1992) 20:248-254. A unifying theory of neurohormonal activation in the progression of CHF.
   Google Scholar
• BRISTOW MR: Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am. J. Cardiol. (1993) 71:12C–22C.
   Google Scholar
• PACKER M, LEE WH, KESSLER PD, GOTTLIEB SS, BERNSTEIN JL, KUKIN ML: Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation (1987) 75 (Suppl. IV):80–92.
   Google Scholar
• CHIDSEY CA, HARRISON DC, BRAUNWALD E: Augmenta-tion of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl. J. Med. (1962) 267:650–654.
   PubMed Web of Science ®Google Scholar
• THOMAS JA, MARKS BH: Plasma norepinephrine in congestive heart failure. Am. J. Cardiol (1978) 41:233.
   PubMed Web of Science ®Google Scholar
• SINGAL PK, KAPUR N, DHILLON KS, BEAMISH RE, DHALLA NS: Role of free radicals in catecholamine-induced cardiomyopathy. Can. J. Physiol. Pharmacol (1982) 60:1390–1397.
   PubMed Web of Science ®Google Scholar
• HAGGENDAL J, JONSSON L, JOHANSSON G, BJURSTROM S, CARLSTEN J, THOREN-TOLLING K: Catecholamine-induced free radicals in myocardial cell necrosis on experimental stress in pigs. Acta Physiol. Scand. (1987) 131:447–452.
   PubMedGoogle Scholar
• BRISTOW M, PORT JD: 0-adrenergic blockade in chronic heart failure. Scand. Cardiovasc. J. (1998) 32 (Suppl. 47):45–55.
   Google Scholar
• WAAGSTEIN F, HJALMARSON A, VARNAUSKAS E et al.: Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br. Heart J. (1975) 37:1022–1036.
   PubMedGoogle Scholar
• KRUM H: Beta-adrenoreceptor blockers in chronic heart failure - a review. Br. J. Clin. Pharmacol (1997) 44:111–118.
   PubMed Web of Science ®Google Scholar
• THE MDC TRIAL STUDY GROUP: Metoprolol in DilatedCardiomyopathy: multicenter randomized placebo-controlled trial. Lancet (1993) 342:1441–1446.
   PubMedGoogle Scholar
• GOLDSTEIN 5: Clinical studies on beta blockers andheart failure preceding the MERIT-HF trial. Am. J. Cardiol. (1997) 80 (Suppl. 9B):50J–53J.
   Google Scholar
• WAAGSTEIN F, BRISTOW MR, SWEDBERG K et al.: Benefi-cial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet (1993) 342:1441–1446.
   PubMed Web of Science ®Google Scholar
• WAAGSTEIN F, WAHLQVIST I, ANDERSSON B et al: Metoprolol prevents left ventricular dilatation and increases exercise ejection fraction to the same extent in idiopathic and ischemic cardiomyopathy. Eur. Heart J. (1998) 19(Suppl.):307.
   Google Scholar
• THE METOPROLOL IN DILATED CARDIOMYOPATHY (MDC) TRIAL STUDY GROUP: 3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. Lancet (1998) 351:1180–1181.
   Web of Science ®Google Scholar
• EICHHORN EJ, HEESCH CM, BARNET J et al.: Effect ofmetoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. (1994) 24:1310–1320.
   PubMed Web of Science ®Google Scholar
• WAAGSTEIN F, FOR THE METOPROLOL IN MILD TO MODERATE HEART FAILURE STUDY GROUP: Metoprolol in addition to ACE-inhibitors causes regression of left ventricular dilatation and increases exercise ejection fraction in ischemic cardiomyopathy. J. Am. Coll. Cardiol (1997) 29 (Suppl. A):206A.
   Google Scholar
• THE MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353:2001–2007.
   PubMed Web of Science ®Google Scholar
• ••The largest mortality trial of I3-blockers in CHF performed todate, MERIT-HF showed a significant 34% reduction in the risk of death in patients treated with the long-acting formula-tion of the 13–1 selective agent metoprolol.
   Google Scholar
• SANDBERG A, RAGNARSSON G, JONSSON UE, SJOGREN J: Design of a new multiple-unit controlled-release formulation of metoprolol: metoprolol CR/XL. Eur. J. Clin. Pharmacol. (1988) 33 (Suppl.):S3–7.
   Google Scholar
• WIKSTRAND J, KENDALL M: The role of beta receptor blockade in preventing sudden death. Eur. Heart J. (1992) 13 (Suppl. D):111–120.
   Google Scholar
• CIBIS INVESTIGATORS AND COMMITTEES: A random-ized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study. Circulation (1994) 90:1765–1773.
   PubMed Web of Science ®Google Scholar
• PACKER M: Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. Am. J. Cardiol. (1997) 80 (Suppl. 11A):46L–54L.
   Google Scholar
• ••An excellent review of the rationale for I3-blockade in CHFand of the early clinical trials of I3-blockers in patients with chronic heart failure; it also addresses in detail many of the questions raised by the results of these early trials.
   Google Scholar
• POOLE-WILSON, PA: The Cardiac Insufficiency Bisoprolol Study II (letter). Lancet (1999) 353:1360
   PubMed Web of Science ®Google Scholar
• ANTHONIO RL, BROUWER J, LECHAT, P et al.: Differenteffects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]) . Am. J. Cardiol. (1999) 83:1286–1289.
   PubMed Web of Science ®Google Scholar
• CIBIS-II INVESTIGATORS AND COMMITTEES: The Cardiac Insufficiency Bisoprolol Study II (CIBIS40: a randomised trial. Lancet (1999) 353:9–13.
   PubMed Web of Science ®Google Scholar
• ••The first large-scale mortality trial of I3-blockers in CHF,CIBIS-II demonstrated a 34% reduction in mortality associ-ated with treatment with bisoprolol compared to placebo.
   Google Scholar
• BRISTOW MR, LARRABEE P, MINOBE W et al.: Receptorpharmacology of carvedilol in the human heart. J. Cardiovasc. Pharmacol. (1992) 19(Suppl. I) :S68–580.
   Google Scholar
• AUSTRALIA-NEW ZEALAND HEART FAILURE RESEARCHCOLLABORATIVE GROUP: Effects of carvedilol, a vasodilator-p-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation (1995) 92:212–218.
   PubMed Web of Science ®Google Scholar
• AUSTRALIA/NEW ZEALAND HEART FAILURE RESEARCHCOLLABORATIVE GROUP: Randomised, placebo-controlled trial of carvedilol in patients with conges-tive heart failure due to ischaemic heart disease. Lancet (1997) 349:375–380.
   Google Scholar
• OLSEN SL, GILBERT EM, RENLUND DG et al: Carvedilolimproves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J. Am. Coll. Cardiol. (1995) 25:1225–1231.
   PubMed Web of Science ®Google Scholar
• LOWES BD, GILL EA, RODRIGUEZ-LARRAIN J et al.:Carvedilol is associated with a reversal of remodeling in chronic heart failure (abstract). Circulation (1996) 94 (Suppl. 0:1–407.
   Google Scholar
• BRISTOW MR, GILBERT EM, ABRAHAM WT et al. FOR THEMOCHA INVESTIGATORS: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation (1996) 94:2807–2816.
   PubMed Web of Science ®Google Scholar
• PACKER M, COLUCCI WS, SACKNER-BERNSTEIN JD et al.FOR THE PRECISE STUDY GROUP: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circula-tion (1996) 94:2793–2799.
   PubMed Web of Science ®Google Scholar
• COLUCCI WS, PACKER M, BRISTOW MR et al. FOR THE USCARVEDILOL HEART FAILURE STUDY GROUP: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation (1996) 94:2800–2806.
   PubMed Web of Science ®Google Scholar
• PACKER M, BRISTOW MR, COHN JN et al. FOR THE US CAR VEDILOL HEART FAILURE STUDY GROUP: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl. J. Med. (1996) 334(201349–1355.
   Google Scholar
• ••Mortality and morbidity results of the overall US CarvedilolHeart Failure Program. Although not a traditional prospec-tively designed mortality trial, there was a significant survival benefit with carvedilol compared to placebo. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(11)
   Google Scholar
• BRISTOW MR, RODEN RL, LOWES BD, GILBERT EM, EICHHORN EJ: The role of third-generation beta-blocking agents in chronic heart failure. Clin. Cardiol. (1998) 21 (Suppl. I):13–113.
   Google Scholar
• HERSHBERGER RE, WYNN JR, SUNDBERG L, BRISTOWMR: Mechanism of action of bucindolol in human ventricular myocardium. J. Cardiovasc. Pharmacol. (1990) 15:959–967.
   PubMed Web of Science ®Google Scholar
• EICHHORN EJ, BEDOTTO JB, MALLOY CR et al.: Effect of8-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile, and diastolic perform-ance with bucindolol. Circulation (1990) 82:473–483.
   PubMed Web of Science ®Google Scholar
• GILBERT EM, ANDERSON JL, DEITCHMAN D et al.: Chronic 8-blocker-vasodilator therapy improved cardiac function in idiopathic dilated cardiomyopa-thy: a double blind, randomized study of bucindolol versus placebo. Am. J. Med. (1990) 88:223–229.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR, GILBERT EM, FRENCH WJ, LEATHERMAN G, KANTROWITZ NE, DEITCHMAN D: Dose response of beta blocker therapy in heart failure: a multicenter, randomized trial of bucindolol versus placebo. Circulation (1990) 82 (Supp1.3):111–674.
   Google Scholar
• EICHHORN EJ, MCGHIE I, BEDOTTO JB et al.: Effects of bucindolol on neurohormonal activation in conges-tive heart failure. Am J. Cardiol. (1991) 67:67–73.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR, O'CONNELL JB, GILBERT EM et al., FOR THEBUCINDOLOL INVESTIGATORS: Dose-response of chronic 8-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation (1994) 89:1632–1642.
   Google Scholar
• THE BEST STEERING COMMITTEE: Design of the beta-blocker evaluation survival trial (BEST). Am. J. Cardiol. (1995) 75:1220–1223.
   PubMed Web of Science ®Google Scholar
• BUSINESS WIRE HEALTH SERVICE ON THE INTERNET: Trial terminated with no statistically significant survival advantage. 7/30/99
   Google Scholar
• HABER HL, SIMEK CL, GIMPLE LW et al.: Why do patients with congestive heart failure tolerate the initiation of 8-blocker therapy? Circulation (1993) 88: 1610-1619.
   Google Scholar
• KUKIN ML, KALMAN J, MANNINO MM, BUCHHOLZ-VARLEY C, OCAMPO 0: 13 blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses. Heart (1997) 78:444–449.
   PubMed Web of Science ®Google Scholar
• EICHHORN EJ: Restoring function in failing hearts: the effects of beta blockers. Am. J. Med. (1998) 104:163–169.
   PubMed Web of Science ®Google Scholar
• SACKNER-BERNSTEIN J, KRUM H, GOLDSMITH RL et al.:Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? (abstract). Circulation (1995) 92 (Suppl. 1): 1–395.
   Google Scholar
• •Highlights the need to aggressively manage the side effects associated with the initiation and uptitration of I3-blockers in CHF, as patients who have difficulties during this period obtain the same benefit as those without such adverse effects if they are able to be maintained on therapy.
   Google Scholar
• EICHHORN EJ, BRISTOW MR: Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am. J. Cardiol. (1997) 79:794–798.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of the practicalities of managingpatients with congestive heart failure on I3-blockers.
   Google Scholar
• BRISTOW MR, O'CONNELL JB, GILBERT EM et al. FOR THE BUCINDOLOL INVESTIGATORS: Dose-response of chronic 8-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation (1994) 89:1632–1642.
   Google Scholar
• COHN JN, FOWLER MB, BRISTOW MR et al. FOR THE US CAR VEDILOL HEART FAILURE STUDY GROUP: Safety and efficacy of carvedilol in severe heart failure. J. Card. Fail. (1997) 3:173–179.
   PubMedGoogle Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA et al. ON BEHALF OF THE SAVE INVESTIGATORS: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl. J. Med. (1992) 327:669–677.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. (1992) 327:685–691.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl. J. Med. (1991) 325:293–302.
   PubMed Web of Science ®Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl. J. Med. (1987) 316:1429–1435.
   PubMed Web of Science ®Google Scholar
• THE DIGITALIS INVESTIGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl. J. Med. (1997) 336:525–533.
   PubMed Web of Science ®Google Scholar
• EICHHORN EJ, LUKAS MA, SHUSTERMAN N: Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity (abstract). Circulation (1998) 98 (Suppl. 1)1–365.
   Google Scholar
• CONSTANT J: A review of why and how we may use beta-blockers in congestive heart failure. Chest (1998) 113:800–808.
   PubMed Web of Science ®Google Scholar
• YAMADA T, FUKUNAMI M, OHMORI M et aL Whichsubgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J. Am. Coll. Cardiol. (1993) 21:628–633.
   PubMed Web of Science ®Google Scholar
• YAMADA T, ABE Y, FUKUNAMI M et al.: Could effective-ness of long term 0-blocker therapy for dilated cardiomyopathy be predicted by signal-averaged electrocardiography? (abstract). Circulation (1995) 92 (Suppl.I):1–73.
   Google Scholar
• SUWA M, TAKAHIDE I, YOSHIAKI 0 et al.: Myocardial integrated ultrasonic backscatter in patients with dilated cardiomyopathy: prediction of response to beta-blocker therapy (abstract). Circulation (1998) 98 (Suppl. D:1-365. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(11)
   Google Scholar
• HENDERSON EB, KAHN JK, CORBETT JR et al.: Abnormal 1-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyo-pathy. Circulation (1988) 78:1192–1199.
   PubMed Web of Science ®Google Scholar
• MERLET P, VALETTE H, DUBOIS-RANDE J-L et al.: Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J. Nucl. Med. (1992) 33:471–477.
   PubMed Web of Science ®Google Scholar
• SUWA M, OTAKE Y, MORIGUCHI A et al.: Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to 6-blocker therapy in patients with dilated cardiomyopathy. Am. Heart J. (1997) 133:353–358.
   PubMed Web of Science ®Google Scholar
• KAKUCHI H, SASAKI Y, KOMAMURA K,MIYATAKE K: Clinical usefulness of 1231 meta-iodobenzylguanidine imaging in predicting the effectiveness of 13 blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart (1999) 81:148–152.
   PubMed Web of Science ®Google Scholar
• •The latest technique being developed to help non-invasively guide patient selection for I3-blocker therapy.
   Google Scholar
• BRISTOW MR, HERSHBERGER RE, PORT JD et al.: 6-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation (1990) 82(Suppl.
   Google Scholar
• GILBERT EM, ABRAHAM WT, OLSEN S eta].: Comparative hemodynamic, LV functional, and anti-adrenergic effects of chronic treatment with metoprolol vs. carvedilol in the failing heart. Circulation (1996) 94:2817–2825.
   Google Scholar
• NEWTON GE, PARKER JD: Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation (1996) 94:353–358.
   PubMed Web of Science ®Google Scholar
• YUE TL, CHENG HY, LYSKO PG et al.: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. (1992) 263:92–98.
   PubMed Web of Science ®Google Scholar
• FEUERSTEIN GZ, YUE TL, CHENG HY, RUFFOLO RR: Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J. Hypertens. (1993) 11:S41–S48.
   Web of Science ®Google Scholar
• MCMURRAY J, MCLAY J, CHOPRA M, BRIDGES A, BELCH JJF: Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. (1990) 65:1261–1262.
   PubMed Web of Science ®Google Scholar
• BELCH JJF, BRIDGES AB, SCOTT N, CHOPRA M: Oxygen free radicals and congestive heart failure. Br. Heart J. (1991) 65:245–248.
   PubMedGoogle Scholar
• SOBOTKA PA, BROTTMAN MD, WEITZ Z, BIRNBAUM AJ, SKOSEY JL, ZARLING EJ: Elevated breath pentane in heart failure reduced by free radical scavenger. Free Rad. Biol. Med. (1993) 14:643–647.
   PubMed Web of Science ®Google Scholar
• MCMURRAY J, CHOPRA M, ABDULLAH I, SMITH WE, DARGIE HJ: Evidence of oxidative stress in chronic heart failure in humans. Eur. Heart J. (1993) 14:1493–1498.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ R, KUKIN M: Oxidative stress and conges-tive heart failure. Cong. Heart Failure (1999) 5:153–163.
   PubMedGoogle Scholar
• •An up-to-date review of the evidence supporting the role of oxidative stress in the progression of CHF.
   Google Scholar
• DOUGHTY RN, RODGERS A, SHARPE N, MACMAHON S:Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomized controlled trials. Eur. Heart J. (1997) 18:560–565.
   PubMed Web of Science ®Google Scholar
• HEIDENREICH PA, LEE TT, MASSIE BM: Effect ofbeta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. (1997) 30:27–34.
   PubMed Web of Science ®Google Scholar
• LECHAT P, PACKER M, CHALON S, CUCHERAT M, ARAB T,BOISSEL JP: Clinical effects of B-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled randomized trials. Circulation (1998) 98:1184–1191.
   PubMed Web of Science ®Google Scholar
• SANDERSON JE, CHAN SKW, YU CM et al.: Bblockers in heart failure: a comparison of a vasodilating 6-blocker with metoprolol. Heart (1998) 79:86–92.
   PubMed Web of Science ®Google Scholar
• METRA M, NODARI S, GARBELLINI M eta].: Comparative effects of metoprolol and carvedilol on resting and peak exercise hemodynamics and functional capacity in patients with chronic heart failure. Circulation (1997) 96 (Suppl):1577–1578.
   Google Scholar
• ABRAHAM WT, TSVETKOVA T, LOWES BD, FERGUSONDA, GILBERT EM, BRISTOW MR: Carvedilol improves renal hemodynmaics in patients with chronic heart failure. Circulation (1998) 98 (Suppl.):1378–1379.
   Google Scholar
• KUKIN ML, KALMAN J, CHARNEY RH et al.: Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation (1999) 99:2645–2651.
   PubMed Web of Science ®Google Scholar
• ••In a direct comparison of the nonselective agent carvedilolto the 13–1 selective drug metoprolol, parallel improvements were demonstrated with respect to anti-oxidant activity and other measures with no between group differences.
   Google Scholar
• SANDERSON JE, CHAN S, YIP G et al.: Beta blockers inheart failure: A randomized double blind trial of carvedilol and metoprol. J. Am. Coll Cardiol. (1999) 33 (Suppl.):183A.
   Google Scholar
• DI LENARDA A, SABBADINI G, SALVATORE L et al.:Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J. Am. Coll Cardiol. (1999) 33:1926–34.
   PubMed Web of Science ®Google Scholar
• DOUGHERTY AH, NACCARELLI GV, GRAY EL, HICKS CH,GOLDSTEIN RA: Congestive heart failure with normal systolic function. Am. J. Cardiol (1984) 54:778–782.
   PubMed Web of Science ®Google Scholar
• SOUFER R, WOHLGELERNTER D, VITA N et al.: Intactsystolic left ventricular function in clinical congestive heart failure. Am. J. Cardiol. (1985) 55:1032-1036. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(11)
   Google Scholar
• CARROLL JD, LANG RM, NEUMANN AL, BOROW KM, RAJFER SI: The differential effects of positive inotropic and vasodilator therapy on diastolic properties in patients with congestive cardiomyopathy. Circula-tion(1986) 74:815–825.
   PubMed Web of Science ®Google Scholar
• BRUTSAERT DL, SYS SU, GILLEBERT TC: Diastolic failure:pathophysiology and therapeutic implications. J. Am. Coll. Cardiol (1993) 22:318–325.
   PubMed Web of Science ®Google Scholar
• SETARO JF, SOUFER R, REMETZ MS, PERLMUTTER RA, ZARET BL: Long-term outcome in patients with conges-tive heart failure and intact systolic left ventricular performance. Am. J. Cardiol (1992) 69:1212–1216.
   PubMed Web of Science ®Google Scholar
• COHN JN, JOHNSON G: Heart failure with normal ejection fraction. The V-HeFT Study. Circulation (1990) 81:11148–53.
   Google Scholar
• ANDERSSON B, CAIDAHL K, DI LENARDA A et al.: Changes in early and late diastolic filling patterns induced by long-term 6-adrenergic blockade in patients with idiopathic dilated cardiomyopathy. Circulation (1996) 94:673–682.
   Google Scholar
• PACKER M, COHN JN on behalf of the steering committeeand membership of the advisory council to improve outcomes nationwide in heart failure: Consensus recommendations for the management of heart failure. Am. J. Cardiol. (1999) 83 (Supp1.2A):17A–22A.
   Google Scholar